vs
Side-by-side financial comparison of AMERICAN BATTERY TECHNOLOGY Co (ABAT) and Citius Pharmaceuticals, Inc. (CTXR). Click either name above to swap in a different company.
AMERICAN BATTERY TECHNOLOGY Co is the larger business by last-quarter revenue ($4.8M vs $3.9M, roughly 1.2× Citius Pharmaceuticals, Inc.). AMERICAN BATTERY TECHNOLOGY Co runs the higher net margin — -195.0% vs -238.2%, a 43.2% gap on every dollar of revenue.
American Battery Technology Company, formerly American Battery Metals Corporation, is a US-based battery recycling technology startup founded in 2011. It employs a hydrometallurgical process to recycle batteries and a targeted extraction system to extract raw materials from primary resources.
Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing innovative prescription therapies addressing unmet medical needs across critical care, oncology, anti-infective treatment, and supportive care segments, primarily serving the U.S. healthcare market.
ABAT vs CTXR — Head-to-Head
Income Statement — Q2 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $4.8M | $3.9M |
| Net Profit | $-9.3M | $-9.4M |
| Gross Margin | -33.6% | 80.0% |
| Operating Margin | -207.5% | -228.7% |
| Net Margin | -195.0% | -238.2% |
| Revenue YoY | 1331.8% | — |
| Net Profit YoY | 30.7% | 8.6% |
| EPS (diluted) | $-0.07 | $-0.38 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $4.8M | $3.9M | ||
| Q3 25 | $937.6K | — | ||
| Q2 25 | $2.8M | — | ||
| Q1 25 | $980.0K | — |
| Q4 25 | $-9.3M | $-9.4M | ||
| Q3 25 | $-10.3M | — | ||
| Q2 25 | $-10.2M | — | ||
| Q1 25 | $-11.5M | — |
| Q4 25 | -33.6% | 80.0% | ||
| Q3 25 | -375.1% | — | ||
| Q2 25 | -92.6% | — | ||
| Q1 25 | -274.5% | — |
| Q4 25 | -207.5% | -228.7% | ||
| Q3 25 | -1080.8% | — | ||
| Q2 25 | -280.1% | — | ||
| Q1 25 | -1086.3% | — |
| Q4 25 | -195.0% | -238.2% | ||
| Q3 25 | -1098.5% | — | ||
| Q2 25 | -366.4% | — | ||
| Q1 25 | -1173.1% | — |
| Q4 25 | $-0.07 | $-0.38 | ||
| Q3 25 | $-0.09 | — | ||
| Q2 25 | $-0.09 | — | ||
| Q1 25 | $-0.14 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $47.9M | $7.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $119.0M | $80.0M |
| Total Assets | $123.3M | $140.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $47.9M | $7.7M | ||
| Q3 25 | $30.9M | — | ||
| Q2 25 | $7.5M | — | ||
| Q1 25 | $7.8M | — |
| Q4 25 | $119.0M | $80.0M | ||
| Q3 25 | $96.0M | — | ||
| Q2 25 | $70.6M | — | ||
| Q1 25 | $65.6M | — |
| Q4 25 | $123.3M | $140.4M | ||
| Q3 25 | $101.5M | — | ||
| Q2 25 | $84.5M | — | ||
| Q1 25 | $76.5M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-9.8M | $-13.0M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-9.8M | $-13.0M | ||
| Q3 25 | $-7.1M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $-10.3M | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
